Formulation and characterization of bufadienolides-loaded nanostructured lipid carriers

Drug Development and Industrial Pharmacy

Volumn 36, Issue 5, 2010, Pages 508-517

  Li, Fang ^a   Wang, Yanjiao ^a   Liu, Zitong ^a   Lin, Xia ^a   He, Haibing ^a   Tang, Xing ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bufadienolides; Differential scanning calorimetry; Enzymolysis; In vitro release; Nanostructured lipid carriers; X ray diffraction

Indexed keywords

BUFADIENOLIDE DERIVATIVE; BUFALIN; BUFOGENIN; CINOBUFAGIN; DEOXYCHOLATE SODIUM; DRUG CARRIER; GLYCEROL STEARATE; MEDIUM CHAIN TRIACYLGLYCEROL; NANOSTRUCTURED LIPID CARRIER; OLEIC ACID; POLOXAMER; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DEGRADATION; DRUG FORMULATION; DRUG STABILITY; EMULSION; ENCAPSULATION; FREEZE DRYING; HUMAN; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PH; PLASMA; RAT; THERMAL ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

AMPHIBIAN VENOMS; ANIMALS; BUFANOLIDES; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; LIPIDS; NANOSTRUCTURES; RATS; X-RAY DIFFRACTION;

EID: 77952615759     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903264397     Document Type: Article

References (29)

1. Krenn L, Kopp B. (1998). Bufadienolides from animal and plant sources. Photochemistry, 48: 1-29.
2. Steyn PS, Van Heerden FR. (1998). Bufadienolides of plant and animal origin. Nat Prod Rep, 15: 397-413.
3. Hashimoto S, Jing Y, Kawazoe N, Masuda Y, Nakajo S, Yoshida T, et al. (1997). Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. Leuk Res, 21: 875-83.
4. Kamano Y, Yamashita A, Nogawa T, Morita H, Takeya K, Itokawa H, et al. (2002). QSAR evaluation of the Chan Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/51. J Med Chem, 45: 5440-7.
5. Yeh JY, Huang WJ, Kan SF, Wang PS. (2003). Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate, 54: 112-24.
6. Chen KK, Kovarikove A. (1967). Pharmacology and toxicology of toad venom. J Pharm Sci, 56: 1535-41.
7. Li F, Yang R, Weng Y, Tang X. (2009). Preparation and evaluation of lyophilized liposome-encapsulated bufadienolides. Drug Dev Ind Pharm, 35: 1048-58.
8. Müller RH, Petersen RD, Hommoss A, Pardeike J. (2007). Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev, 59: 522-30.
9. Müller RH, Radtke M, Wissing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 54: 131-55.
10. Müller RH, Radtke M, Wissing SA. (2002). Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm, 242: 121-8.
11. Garcia-Fuentes M, Aolores MJ, Torres D. (2005). Design and characterization of a new drug nanocarrier made from solid-liquid lipid mixtures. J Colloid Interface Sci, 285 (2): 590-8.
12. Joshi MD, Müller RH. (2009). Lipid nanoparticles for parenteral delivery of actives. Adv Drug Deliv Rev, 71 (2): 161-72.
13. Joshi M, Patravale V. (2006). Formulation and evaluation of nanostructured lipid carrier (NLC) -based gel of valdecoxib. Drug Dev Ind Pharm, 32: 911-8.
14. Müller RH, Rühl D, Runge S, Schulze-Forster K, Mehnert W. (1997). Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res, 14: 458-62. (Pubitemid 27205004)
15. Hu LD, Tang X, Cui FD. (2004). Solid-lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol, 56: 1527-35.
16. Müller RH, Schmidt S, Buttle I, Akkar A, Schmitt J, Brömer S. (2004). Solemuls-novel technology for the formulation of i.v. emulsion with poorly soluble drugs. Int J Pharm, 269: 293-302.
17. Liu X, Zhang Y, Tang X, Zhang HY. (2009). Determination of entrapment efficiency and drug phase distribution of submicron emulsions loaded silybin. J Microencapsul, 26: 180-6.
18. Joshi M, Patravale V. (2008). Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm, 346: 124-32.
19. Yuan H, Wang LL, Du YZ, You J, Hu FQ, Zeng S. (2007). Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B Biointerfaces, 60: 174-9.
20. Zhang XX, Pan WS, Gan L, Zhu CL, Gan Y, Nie SF. (2008). Preparation of a Dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem Pharm Bull, 56: 1645-50.
21. Liu K, Sun J, Wang Y, He Y, Gao K, He ZG. (2008). Preparation and characterization of 10-hydroxycamptothecin loaded nanostructured lipid carriers. Drug Dev Ind Pharm, 34: 465-71.
22. Lim SJ, Kim CK. (2002). Formulation parameters determining the physicochemical characteristics of solid-lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm, 243: 135-46.
23. Müller RH, Rühl D, Runge SA. (1996). Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm, 144: 115-21.
24. ™) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm, 52: 203-10.
25. Plock N, Kloft C. (2005). Microdialysis-theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci, 25: 1-24.
26. Jenning V, Thünemann AF, Gohla SH. (2000). Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm, 199: 167-77.
27. Wissing SA, Kayser O, Müller RH. (2004). Solid-lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 56: 1257-72.
28. Hu FQ, Jiang SP, Du YZ. (2005). Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces, 45: 167-73.
29. zur Mühlen A, zur Mühlen E, Niehus H, Mehnert W. (1996). Atomic force microscopy studies of solid lipid nanoparticles. Pharm Res, 13: 1411-6.